Hims & Hers Health, Inc. (HIMS)
Stock Market Today, March 12: Hims and Hers Health Drops After Rally Sparks Profit Taking
Expand NYSE: HIMS Hims & Hers Health Today's Change (-7.75%) $-2.00 Current Price $23.88 Key Data Points Market Cap $5.9B Day's Range $23.77 - $27.20 52wk Range $13.74 - $70.43 Volume 2.1M Avg Vol 30M Gross Margin 60.86%
Hims & Hers Plunges 29.4% in Three Months: How to Play the Stock?
HIMS is navigating margin and regulatory pressure, but new benefits, a Novo Nordisk tie-up and platform growth could drive its next move.
Eli Lilly Stock Slips After Warning on Compounded GLP-1 Drugs With Additives
Shares of Eli Lilly and Company (LLY) slipped about 1% in early Thursday trading after the drugmaker cautioned about potential safety concerns tied to compounde
Is Hims & Hers Really the Growth Stock to Buy That It Appears?
Hims & Hers Health ( NYSE:HIMS ) looked like a fallen growth star earlier this year.
Hims & Hers Health And Novo Nordisk: A Corporate Remarriage That May Work Out Profitably
Hims & Hers Health (HIMS) is rated a Speculative Buy after its renewed partnership with Novo Nordisk, providing legitimate access to lucrative branded GLP-1 therapies. HIMS has demonstrated rapid revenue growth and improving profitability, with gross margins rising from 30% to nearly 75% and operating income turning positive. Valuation appears reasonable given future earnings growth potential, though current multiples are above sector averages on earnings but below on sales.
Hims & Hers: The Novo Nordisk Deal Changes Everything
The Novo Nordisk partnership legitimizes Hims & Hers' business model by replacing compounded GLP-1 sales with branded Wegovy and Ozempic distribution. Hims generated $2.35B revenue in 2025 (+59% YoY) with $318M EBITDA and $300M operating cash flow, demonstrating strong platform economics. The company ended 2025 with 2.5M+ subscribers and $83 average monthly revenue per user, reflecting growing cross-selling across health categories.
This Novo Nordisk Partnership Shows That HIMS Has All The Leverage
Hims & Hers (HIMS) is still a Strong Buy, given that the transformative partnership with Novo Nordisk resolves legal risks and unlocks new growth avenues. HIMS' core value lies in its 2.5M+ cash-pay customer base, enabling leverage with major pharma and supporting expansion into branded drug programs. With the Novo deal, I anticipate 2026 revenue could exceed $3.1B, sustaining 20%+ annual growth through 2029 and materially improving EBITDA margins.
Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang — Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook
Two healthcare names are drawing fresh analyst attention this week as Wall Street recalibrates around a landmark GLP-1 truce and a fertility benefits company navigating a murky 2026 outlook.
Hims and Hers Expands Consumer-Focused Digital Health Platform
HIMS expands its digital care platform with new specialties, lab testing and global moves as it scales personalized telehealth services.
Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles
Three health-technology names are drawing fresh analyst attention this week as strategic partnerships and business pivots reframe the risk-reward calculus for each.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is HIMS stock the best buy in March 2026?
Shares of Hims & Hers Health (NYSE: HIMS) have staged a sharp rebound after drugmaker Novo Nordisk (NYSE: NVO) dropped its lawsuit against the company, removing what many investors considered the biggest risk.
